

TMDA/DMC/MRE/F/016  
Rev #:02



THE UNITED REPUBLIC OF TANZANIA

MINISTRY OF HEALTH



TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY

**PUBLIC ASSESSMENT REPORT FOR OLOPAT (OLOPATADINE HYDROCHLORIDE USP 0.1%  
W/V) OPHTHALMIC SOLUTION**

Version number 1.0  
21 August, 2023

TMDA Headquarters, Plot No. 56/1, Block E, Kisasa B Centre, Hombolo Road, P. O. Box  
1253, Dodoma – Tanzania, Telephone: +255 (26) 2961989/2061990/+255 (22)  
2450512/2450751/2452108, Email: [info@tmda.og.tz](mailto:info@tmda.og.tz), Website: [www.tmda.go.tz](http://www.tmda.go.tz)

Toll free: 0800110084

Effective date: 03/10/2022

## 1. Introduction

OLOPAT ophthalmic solution is a generic medicinal product containing the active substance Olopatidine Hydrochloride. The originator product is "Opatanol eye drops solution" by Novartis Europharm Ltd., The United Kingdom. Olopatidine hydrochloride is a potent histamine antagonist with high selectivity for H1- compared to H2- and H3-receptors and no significant activity on  $\alpha$ -adrenergic and serotonin receptors. After ophthalmological administration, olopatidine does not significantly affect the pupil diameter, but inhibits the release of pro-inflammatory cytokines by human conjunctival epithelial cells and may similarly act on mast cells. OLOPAT ophthalmic solution is approved in Tanzania for use in adults and children ( $\geq 3$  years).

### Product details

Registration number	TAN 23 HM 0265
Brand name	OLOPAT
Generic name, strength, and form	Olopatidine Hydrochloride equivalent to Olopatidine 0.1% w/v
ATC classification	S01GX09- Ophthalmological (Decongestants and antiallergics)
Distribution category	POM
Country of origin	India
Associated product	N/A
Marketing Authorization Holder	Ajanta Pharma Limited Ajanta House, Charkop, Kandvil (W), Mumbai 400067, India.
Local Technical Representative	Astra Pharma (T) Ltd Plot No. 12, Vingunguti Industrial Area, Nyerere Road, Opp; Pepsi Tanzania Ltd, Kariakoo, Dar es Salaam.

### 1.1 Assessment procedure

The application for registration of OLOPAT was submitted on 26/10/2021. The product underwent full assessment. Assessment was completed in 4 (four) rounds of evaluation and the product was registered on 01/06/2023.

### 1.2 Information for users

Visual description of the finished product	Clear, colourless solution, free from visible particles
Primary packing material	5ml LDPE Vial, along with HDPE cap
Secondary packing materials	Printed carton box
Shelf-life and storage condition	24 months, Do not store above 30 °C 30 days (in-use shelf life)
Route of administration	Ocular

Therapeutic indications	Indicated for the treatment of ocular itching associated with allergic conjunctivitis
-------------------------	---

## 2. Labelling and product information

### Summary of product characteristics

The SmPC included all the relevant information to ensure correct and safe use of the medicine by healthcare providers. The complete SmPC can be accessed [here](#).

### Package insert/leaflet

The package insert is confirmed to be derived from the SmPC and contains sufficient data for the end user. Since the product is POM, the package insert contains full prescribing information as per SmPC.

### Container labels

The product label information is presented in English. Details in the secondary pack label include:

Brand name: OLOPAT

Composition: Olopatadine Hydrochloride equivalent to Olopatadine 0.2% w/v

Pack size: 5 mL

Manufacturing details: batch number, manufacturing date, and expiry date

Storage conditions: Do not above 30°C

Manufacturer address: physical address of release site

Unique identifier: Not applicable

Special warnings/precautions or instructions for use: Not applicable

The details of the primary pack include:

Brand name and strength: OLOPAT

Manufacturing details: batch number, manufacturing date and expiry date

Name of manufacturer: Ajanta Pharma Limited

The content of the primary and secondary labels was aligned to the requirements of the Part V of the Compendium: Guidelines on Format and Content of Product Labels for Medicinal products. The label contains sufficient information for proper identification of the medicine and post marketing follow up of the product.

Mock labels are appended as annex I.

### 3. Scientific discussion

#### Quality of Active Pharmaceutical Ingredients

Information on quality of the API was submitted in form of CEP.

#### General Information

Olopatadine Hydrochloride API is compendia in USP.


Molecular formula:  $C_{21}H_{21}ClNO_3$

Chemical name:

Dibenz [b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino) propylidene-6,11 dihydro-hydrochloride, (Z)-; (or)

11-[(Z)-3-(Dimethylamino) propylidene]-6,11- dihydrodibenzo [b,e] oxepin-2-acetic acid, hydrochloride.

Structure:



#### General properties

Olopatadine Hydrochloride is a white crystalline powder very soluble in Formic acid, sparingly soluble in water, very slightly soluble in dehydrated alcohol. There are polymorphs reported for Olopatadine Hydrochloride. The Olopatadine Hydrochloride manufactured by Indoco exhibits crystalline form I.

Olopatadine Hydrochloride has no chiral centers but can exist as two geometric isomers. The preferred configuration for optimal pharmacological activity is the Z-isomer. The Olopatadine E-isomer is controlled in the drug substance specifications with a limit of not more than 0.10%.

## **Manufacture**

Olopatadine Hydrochloride API manufacturer is Indoco Remedies Limited, Kilolab, R-92/93, 1st floor, T.T.C., M.I.D.C, Thane Belapur Road, Rabale, Navi Mumbai – 400 701, Maharashtra State, India. The manufacturing complies with GMP requirements as evidenced by the GMP certificate issued by the Food and Drug Administration of Maharashtra. Olopatadine Hydrochloride API is manufactured by chemical synthesis using conventional techniques. Sufficient controls of quality of materials and in-process checks were employed throughout the manufacturing process.

## **Specifications**

The API specifications were set as per USP standards and ICHQ3A. The parameters monitored during quality control are: Description, solubility, identity by IR, HPLC, and Chloride, residue on ignition, related substances, loss on drying, pH, assay (HPLC), residual solvent (GC). Compliance to these specifications were established via batch analysis data and stability studies.

### Stability and container closure system

The re-test period of Olopatadine Hydrochloride API is 24 months when packed in original container with storage condition 'Preserve in well closed container'.

## **Quality of the Finished Pharmaceutical Product**

### **Formulation**

OLOPAT is a clear, colourless solution, free from visible particles

OLOPAT OD contains the Olopatadine Hydrochloride and other ingredients listed here after: benzalkonium chloride, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, sodium hydroxide, and water for injections. The quantities of all ingredients are confirmed to be in line with the recommendations of Handbook of Pharmaceutical Excipients, 8<sup>th</sup> Edition in terms of function and quantities.

## **Manufacture**

The finished product manufacturer is Ajanta Pharma Limited, Mirza-Palashbari Road, Village Kokjhar, Kamrup (R), Guwahati, Assam-781128. The compliance of the sites to TMDA GMP standards was confirmed through site inspection on DD/MM/YYYY.

## **Specifications**

The FPP is non-compensated. The manufacturer controls the quality of the finished product as per in-house standards and ICH requirements. The parameters monitored during quality control are: description, identification of API and preservative agent, average filled volume, uniformity of filled volume, pH, clarity of solution, colour of solution, particulate matter, weight per ml, sterility,

osmolality, related substances, and assay of API and preservative agent. Compliance to the standard was established using batch analysis data and stability data.

### Stability and container closure system

Stability studies were conducted on 3(three) batches of the finished product stored at  $30 \pm 2^{\circ}\text{C}$  & RH:  $35 \pm 5\%$  RH for 36 months and  $40 \pm 2^{\circ}\text{C}$  & RH:  $25\% \pm 5\%$  RH for 6 months. Based on the stability data presented, the approved shelf-life is 36 months when stored in LDPE vial with storage condition 'Do not above  $30^{\circ}\text{C}$ '

After opening of vial, the OLOPAT is demonstrated through in-use stability study conducted by using two (2) batches physically and chemically stable for 30 days when store at temperature not above  $30^{\circ}\text{C}$ .

### Safety and efficacy information

OLOPAT is an ophthalmic formulation and therefore fulfils the exemption mentioned in the part III: guidelines on therapeutic equivalence requirements, which states that a bioequivalence study is not required if the ophthalmic products prepared as aqueous solutions and containing the same active pharmaceutical ingredient(s) in the same concentration. The quantitative composition of OLOPAT is entirely the same as the reference products in the market. Therefore, it may be considered as therapeutic equivalent, with the same efficacy/safety profile as known for the active substance of the reference medicinal product. The current product can be used instead of its reference product.

## 4. Benefit-Risk Assessment and Conclusion

On basis of the data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. OLOPAT is recommended for registration.

## 5. Post-approval updates

### Variation applications

Reference number	Date submitted	Change requested	Recommendation	Granting date

### Feedback from pharmacovigilance, post marketing surveillance and enforcement activities

Type of feedback	Impact	Response

### Re-registration applications

Application for renewal of registration was submitted on <DDMMYYYY>. The application was finalized in <number> rounds of evaluation. The product was confirmed to still be compliant to the standards of quality, safety and efficacy, hence registration was renewed on <DDMMYYYY>.

### PART 5: CHANGE HISTORY

Version number	Date	Description of update	Section(s) Modified	Approval date

**Annex I: Mock up labels;**

Primary pack label;



Secondary pack label: